NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $20.30.

NEO has been the subject of a number of recent analyst reports. Bank of America increased their price target on shares of NeoGenomics from $18.00 to $19.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Benchmark cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a research note on Friday, January 10th. Finally, Jefferies Financial Group began coverage on shares of NeoGenomics in a research note on Tuesday, December 10th. They set a “buy” rating and a $22.00 target price for the company.

NeoGenomics Stock Up 1.6 %

Shares of NEO stock opened at $14.21 on Friday. The firm has a fifty day moving average of $16.68 and a 200-day moving average of $15.67. The company has a quick ratio of 1.91, a current ratio of 1.99 and a debt-to-equity ratio of 0.37. NeoGenomics has a 12-month low of $12.13 and a 12-month high of $19.11. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -23.29 and a beta of 1.24.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.01 by $0.04. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The business had revenue of $167.80 million during the quarter, compared to analysts’ expectations of $167.00 million. During the same quarter in the prior year, the company posted ($0.06) earnings per share. The firm’s revenue was up 10.5% on a year-over-year basis. As a group, equities research analysts predict that NeoGenomics will post -0.16 earnings per share for the current fiscal year.

Insider Buying and Selling at NeoGenomics

In related news, General Counsel Alicia C. Olivo sold 5,175 shares of NeoGenomics stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $15.36, for a total transaction of $79,488.00. Following the sale, the general counsel now directly owns 37,129 shares in the company, valued at $570,301.44. This trade represents a 12.23 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Versant Capital Management Inc lifted its position in shares of NeoGenomics by 174.9% in the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock worth $30,000 after purchasing an additional 1,142 shares during the period. Quarry LP acquired a new position in shares of NeoGenomics in the 3rd quarter worth approximately $40,000. Blue Trust Inc. lifted its position in shares of NeoGenomics by 42.3% in the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after purchasing an additional 987 shares during the period. Canada Pension Plan Investment Board bought a new stake in shares of NeoGenomics in the 2nd quarter valued at $57,000. Finally, KBC Group NV increased its stake in shares of NeoGenomics by 33.1% in the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock valued at $67,000 after acquiring an additional 1,127 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.